The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
 
Andrae L. Vandross
Research Funding - Vincerx Pharma (Inst)
 
Brian N. Stein
Employment - Icon Group
Stock and Other Ownership Interests - ICON group
 
Jermaine Coward
Research Funding - AstraZeneca (Inst); Vincerx Pharma (Inst)
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics
Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Amy J. Johnson
Employment - Vincerx Pharma
Stock and Other Ownership Interests - JJ Innovative Medicine; Vincerx Pharma
Patents, Royalties, Other Intellectual Property - Vincerx Pharma
 
Joseph Birkett
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Aura Biosciences; Centessa Pharmaceuticals (I); Vincerx Pharma
Consulting or Advisory Role - Aura Biosciences; Ellipses Pharma; Kura Oncology
Travel, Accommodations, Expenses - Aura Biosciences
 
Xin Huang
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Melanie M. Frigault
Employment - AstraZeneca; Vincerx Pharma, Inc.
Stock and Other Ownership Interests - Vincerx Pharma, Inc.
Honoraria - DeciBio
Patents, Royalties, Other Intellectual Property - MET mutation that confers sensitivity to a selective MET inhibitor
Travel, Accommodations, Expenses - Vincerx Pharma, Inc.
 
Hans-georg Lerchen
Employment - Vincerx Pharma GmbH
Leadership - Vincerx Pharma GmbH
Stock and Other Ownership Interests - Bayer; Vincerx Pharma
Research Funding - Vincerx Pharma
 
Beatrix Stelte-Ludwig
Employment - Centessa Pharmaceuticals (I); Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma; Vincerx Pharma (I)
Patents, Royalties, Other Intellectual Property - Bayer; Vincerx Pharma
 
Tasheda Navarro
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Jim Peck
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Lilly; Vincerx Pharma
 
Wyatt Gross
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Raquel Izumi
Employment - Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
Patents, Royalties, Other Intellectual Property - Acerta Pharma
 
Ahmed M. Hamdy
Employment - Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
Patents, Royalties, Other Intellectual Property - acalabrutinib multiple patents; multiple patents
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Syneos Health